Matthew J. Baker, PharmD

AXS-05 (Dextromethorphan-Bupropion) Improves Depressive Symptoms and Functioning in Patients with One Prior Treatment Failure: Results from the EVOLVE Long-Term, Open-Label Study

Abstract: Background: In STAR*D, following non-remission with an SSRI, remission rates for second line treatments were ~ 25% regardless of the switch strategy employed. Antidepressants ...

Matthew J. Baker , PharmD;

Zachariah Thomas , DPM, AACFAS;

01/19/2023

Case Study

Collaborative Experience Using the LARIAT System for Left Atrial Appendage Closure

09/25/2013

Eugene H. Chung , MD, MSc, MS, MPH, FHRS;

Matthew J. Baker , PharmD;

J. Paul Mounsey , PhD, BMBCh, MRCP, FACC;

Andy C. Kiser , MD;

Percutaneous left atrial appendage ligation utilizing the LARIAT Suture Delivery Device is a fascinating and feasible procedure for LAA obliteration.

Percutaneous left atrial...

09/25/2013

EP Lab Digest

Assessment of Withdrawal Symptoms after Discontinuation of AXS-05 (Dextromethorphan-Bupropion) Treatment: Results from the GEMINI Trial

The GEMINI trial evaluated withdrawal symptoms in MDD patients after a 6-week treatment with AXS-05. Upon discontinuation, symptoms were assessed using the PWC-20. Results showed no signi...

Matthew J. Baker , PharmD;

10/26/2023